• MJHLS Brand Logo

© 2026 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.

Evidence Supports Safe, Effective Switching to Etanercept Biosimilars

January 06, 2026

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for chronic inflammatory diseases.

FDA Approves Amneal Denosumab Biosimilars, Capping Year of Market Expansion

January 06, 2026

Evidence Gaps Continue to Shape Biosimilar Adoption in Pediatric Care

January 05, 2026

Biosimilar Market Momentum: EU Approvals, Strategic Launches, and Major US Partnerships

January 02, 2026

Top 5 Most-Read Biosimilar News of 2025

December 31, 2025

Featured Content

Top 5 Most-Read Gastroenterology Articles of 2025

December 29th 2025

By Skylar Jeremias

Article

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics impacting IBD treatment options.

Top 5 Most-Read Ophthalmology Articles of 2025

December 26th 2025

By Skylar Jeremias

Article

The most-read ophthalmology biosimilar stories of 2025 included FDA approvals and real-world data.

Top 5 Most-Read Bone Health Articles of 2025

December 24th 2025

By Skylar Jeremias

Article

Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in 2025.

BioRationality: Entering a New Era of Affordable Biosimilar Development

December 23rd 2025

By Sarfaraz K. Niazi, PhD

Article

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market and revolutionize access to essential medicines.

Top 5 Most-Read Policy Articles of 2025

December 22nd 2025

By Skylar Jeremias

Article

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers in the pharmaceutical landscape.

Top 5 Most-Read Regulatory Articles of 2025

December 19th 2025

By Skylar Jeremias

Article

Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and competition in health care.

First Natalizumab Biosimilar Tyruko Launches, Expanding Access in Multiple Sclerosis

December 18th 2025

By Skylar Jeremias

Article

Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.

Denosumab, Golimumab Biosimilars Clear Major Regulatory Milestones in Europe, as US Hurdles Remain

December 16th 2025

By Skylar Jeremias

Article

Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.

BioRationality: FDA Issues New Guidance on Promotional Communications for Biosimilar Products

December 11th 2025

By Sarfaraz K. Niazi, PhD

Article

FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading claims in the competitive landscape.

Medicare Modeling Shows Major Savings With Biosimilar Bevacizumab Use

December 9th 2025

By Skylar Jeremias

Article

Biosimilar bevacizumab offers significant cost savings for Medicare, enhancing treatment access for metastatic colorectal and lung cancer patients without increasing spending.